KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 5,104 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 5,104 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $50,121.28. Following the completion of the transaction, the chief executive officer now directly owns 278,855 shares of the company’s stock, valued at approximately $2,738,356.10. The trade was a 1.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

KalVista Pharmaceuticals Stock Up 9.5 %

Shares of NASDAQ KALV opened at $10.71 on Thursday. The company has a market capitalization of $529.27 million, a PE ratio of -2.94 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $15.50. The firm has a fifty day simple moving average of $8.80 and a 200 day simple moving average of $10.43.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.01. As a group, equities analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of KALV. Vestal Point Capital LP boosted its position in shares of KalVista Pharmaceuticals by 73.9% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock worth $46,320,000 after purchasing an additional 1,700,000 shares in the last quarter. Boxer Capital Management LLC bought a new position in KalVista Pharmaceuticals in the fourth quarter worth approximately $13,467,000. Octagon Capital Advisors LP acquired a new stake in KalVista Pharmaceuticals in the fourth quarter valued at approximately $11,604,000. Frazier Life Sciences Management L.P. grew its stake in KalVista Pharmaceuticals by 32.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company’s stock valued at $41,400,000 after acquiring an additional 1,200,000 shares during the period. Finally, Stempoint Capital LP bought a new stake in shares of KalVista Pharmaceuticals during the fourth quarter valued at approximately $8,409,000.

Analyst Ratings Changes

KALV has been the subject of several recent research reports. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an “outperform” rating and a $19.00 price objective on the stock. Finally, Bank of America assumed coverage on KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $22.00 target price for the company. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, KalVista Pharmaceuticals has a consensus rating of “Buy” and an average price target of $23.80.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).